Adela, Inc.
About Adela, Inc.
Adela, Inc. is a biotechnology company developing blood-based tests for minimal residual disease (MRD) monitoring and multi-cancer early detection using a genome-wide methylome enrichment platform. The company was founded in 2020 and is headquartered in Foster City, California. Its tissue-agnostic approach eliminates the need for tumor samples and supports applications across the cancer care continuum. Adela has raised a total of $113M over multiple rounds, with investors including F-Prime Capital, RA Capital Management, OrbiMed, Deerfield Management, and Decheng Capital.
- 🔗 Adela, Inc. Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 Adela Funding, Investors & Competitors | Multiples
- 🔗 Adela - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 ADELA | Adela Debuts with $60M in Series A Financing and a Breakthrough Approach to Blood-Based Detection of Cancer and Other Diseases
- 🔗 ADELA | Adela Announces $48 Million in Financing and Leadership Addition to Advance Tissue-Agnostic Minimal Residual Disease (MRD) Monitoring Product Portfolio Based on Genome-Wide Methylome Approach
Key highlights
- Raised $60M Series A in June 2021 led by F-Prime Capital
- Closed $48M financing in 2023 to commercialize MRD monitoring product
- Uses genome-wide methylome approach for tissue-agnostic cancer testing
- Interim CEO Lisa Alderson appointed in 2023
Ask StreetZero about Adela, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account